Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide versus mesalazine versus placebo for lymphocytic colitis
NL-OMON40316Phase 3Active, not recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- May 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Lymphocytic Colitis (LC) comparing Budenofalk, Salofalk and Placebo (3 arms). Primary endpoint: Clinical remission at week 8. Started May 2014; status: active, not recruiting.
02
Drugs
budesonideSalcrozine
03
Conditions
Lymphocytic Colitis (LC)
Beyond the preview
Go deeper on NL-OMON40316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40316.